INHIBIKASE THERAPEUTICS INC (IKT:NASDAQ)

$2.31 -0.04 (-1.7021%)

watchlist-icon
search-icon
Profile Icon

Most Recent Average Sentiment Analysis Score (0 to 100): 70

negative-sentiment
Negative [0, 35)
neutral-sentiment
Neutral [35, 65]
positive-sentiment
Positive (65, 100]
Visualize Sentiment Trendline

Analysed INHIBIKASE THERAPEUTICS INC (IKT:NASDAQ) News Sources

Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

21-11-2025

yahoo.com

external link

Institutions own 29% of Inhibikase Therapeutics, Inc. (NASDAQ:IKT) shares but individual investors control 41% of the company

08-12-2025

yahoo.com

external link

Sands Capital Opens $10 Million ServiceTitan Position

18-02-2026

fool.com

external link

Bank of America Predicts Up to 240% Jump for These 2 ‘Strong Buy’ Stocks

22-02-2026

yahoo.com

external link

Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity

26-03-2026

yahoo.com

external link

Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension

07-04-2026

yahoo.com

external link

Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity

12-05-2026

yahoo.com

external link

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02-07-2026

yahoo.com

external link

Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility

14-07-2026

yahoo.com

external link

Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH

23-07-2026

yahoo.com

external link

INHIBIKASE THERAPEUTICS INC (IKT:NASDAQ) Sentiment Trend

0 25 50 75 100 73 64 90 77 70 64 63 72 74 54 21-11-2025 08-12-2025 18-02-2026 22-02-2026 26-03-2026 07-04-2026 12-05-2026 02-07-2026 14-07-2026 23-07-2026 #1 #2 #3 #4 #5 #6 #7 #8 #9 #10 Negative < 35 Neutral 35–65 Positive > 65 View FAQ

INHIBIKASE THERAPEUTICS INC (IKT:NASDAQ) FAQs

toggle

What is the current price of INHIBIKASE THERAPEUTICS INC (IKT:NASDAQ)?

The current price of INHIBIKASE THERAPEUTICS INC (IKT:NASDAQ) is $2.31.


toggle

INHIBIKASE THERAPEUTICS INC (IKT:NASDAQ) absolute price change since previous trading day?

The absolute price change of INHIBIKASE THERAPEUTICS INC (IKT:NASDAQ) since the previous trading day is $-0.04.


toggle

INHIBIKASE THERAPEUTICS INC (IKT:NASDAQ) percentage price change since previous trading day?

The percentage price change of INHIBIKASE THERAPEUTICS INC (IKT:NASDAQ) since the previous trading day is -1.7021%.


toggle

What is the most recent average sentiment score for INHIBIKASE THERAPEUTICS INC (IKT:NASDAQ)?

The most recent average sentiment score for INHIBIKASE THERAPEUTICS INC (IKT:NASDAQ) is 70 out of 100.


toggle

What is the most recent average sentiment for INHIBIKASE THERAPEUTICS INC (IKT:NASDAQ)?

The most recent sentiment for INHIBIKASE THERAPEUTICS INC (IKT:NASDAQ) is .


SEC-8K** Filing Available For INHIBIKASE THERAPEUTICS INC (IKT:NASDAQ)

** material developments that could impact a company's financial condition or stock price.

Similar Securities People Also Ask

OKUR (Onkure Therapeutics Inc)
AKTX (Akari Therapeutics ADR)
KTTA (Pasithea Therapeutics Corp)

Author: MattELab

X Icon

GitHub Icon

MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.